

01-16-2008

DEPARTMENT OF COMMERCE  
Patent and Trademark Office

RECORD  
TRA



103475885

To the Director of the U. S. Patent and Trademark

or the new address(es) below.

1.14.08

**1. Name of conveying party(ies):**

Neoprobe Corporation

- Individual(s)       Association
- General Partnership       Limited Partnership
- Corporation- State: Delaware
- Other \_\_\_\_\_

Citizenship (see guidelines) \_\_\_\_\_

Additional names of conveying parties attached?  Yes  No

**2. Name and address of receiving party(ies)**

Additional names, addresses, or citizenship attached?  Yes  No

Name: Platinum-Montaur Life Sciences, LLC

Internal

Address: \_\_\_\_\_

Street Address: 152 West 57th Street, 54th Floor

City: New York

State: New York

Country: USA      Zip: 10019

Association      Citizenship \_\_\_\_\_

General Partnership      Citizenship \_\_\_\_\_

Limited Partnership      Citizenship \_\_\_\_\_

Corporation      Citizenship \_\_\_\_\_

Other LLC      Citizenship Delaware

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

**3. Nature of conveyance /Execution Date(s) :**

Execution Date(s) December 26, 2007

- Assignment       Merger
- Security Agreement       Change of Name
- Other \_\_\_\_\_

**4. Application number(s) or registration number(s) and identification or description of the Trademark.**

A. Trademark Application No.(s)

B. Trademark Registration No.(s)

2432380    3163525    2450105    2762894  
2728058    2322304    2316583    1542372

Additional sheet(s) attached?  Yes  No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):  
BlueTip; neo2000; NeoMax; Neoprobe

**5. Name & address of party to whom correspondence concerning document should be mailed:**

Name: Shane W. McCormack, Esq.

Internal Address: \_\_\_\_\_

Street Address: 30 Main Street  
PO Box 787

City: Burlington

State: VT      Zip: 05402-0787

Phone Number: 802-862-0500

Fax Number: 802-862-8176

Email Address: smccormack@vtlaw1.com

**6. Total number of applications and registrations involved:**

8

**7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ 320.00**

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed

**8. Payment Information:**

a. Credit Card      Last 4 Numbers \_\_\_\_\_  
Expiration Date \_\_\_\_\_

b. Deposit Account Number 0000160783

Authorized User Name \_\_\_\_\_  
CHECK Refund Total: \$105.00

**9. Signature:**

Signature

1/10/08

Date

Shane W. McCormack, Esq.

Name of Person Signing

Total number of pages including cover sheet, attachments, and document: 14

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

01/15/2008 MTA001 00000092 2432380  
01/15/2008 MTA001 0000160783  
02 FC:0522

40.00 OP  
175.00 OP

**PATENT, TRADEMARK  
AND COPYRIGHT SECURITY AGREEMENT**

THIS PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT (this "Agreement") is entered into as of this 26th day of December 2007, by and among NEOPROBE CORPORATION, a Delaware corporation (the "Company"), CARDIOSONIX LTD., a corporation organized under the laws of the State of Israel ("Cardiosonix"), and CIRA BIOSCIENCES INC., a Delaware corporation ("Cira" and jointly and severally with the Company and Cardiosonix, the "Pledgor"), each with its principle address at 425 Metro Place North, Suite 300, Dublin, Ohio 43017-1367, and Platinum-Montaur Life Sciences, LLC (the "Lender").

WHEREAS, the Company and the Lender are parties to a certain Securities Purchase Agreement, dated as of December 26, 2007 (the "Purchase Agreement"), and a Security Agreement, dated as of December 26, 2007 (the "Security Agreement"), which provide for, among other things: (i) the Company to issue to the Lender the Notes identified in the Purchase Agreement; and (ii) the grant by the Company to the Lender of a security interest in the Company's assets.

WHEREAS, to induce the Lender to purchase the Notes pursuant to the Purchase Agreement, the Company has agreed to pledge, and to cause its subsidiaries to pledge, as collateral security for the Company's obligations under the Notes, the assets described herein.

WHEREAS, the extension of credit pursuant to the Notes benefits Cardiosonix and Cira, as subsidiaries of the Company.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Pledgor and the Lender agree as follows:

1. Security Interest in Patents, Trademarks and Copyrights. To secure the complete and timely satisfaction of all of Company's "Obligations" (as that term is defined in the Security Agreement) to the Lender, the Pledgor hereby grants and conveys to the Lender a security interest (having priority over all other security interests except as set forth herein) with power of sale, to the extent permitted by law, in all of its now owned or existing, and hereafter acquired or arising:

- (a) patents, patent applications, including, without limitation, any invention and improvement to a patent or patent application, including without limitation those patents and patent applications listed on Schedule A (being sometimes referred to individually and/or collectively, the "Patents");
- (b) trademarks, registered trademarks and trademark applications, trade names, trade styles, service marks, registered service marks and service mark applications including, without limitation, the registered trademarks,

trademark applications, registered service marks and service mark applications listed on Schedule B and (i) all renewals thereof, (ii) all accounts receivable, income, royalties, damages and payments now and hereafter due and/or payable with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past, present or future infringements and dilutions thereof, and (iii) the right to sue for past, present and future infringements and dilutions thereof, and (iv) all of the Pledgor's rights corresponding thereto throughout the world (all of the foregoing registered trademarks, trademark applications, trade names, trade styles, registered service marks and service mark applications, together with the items described in clauses (i)-(iv) in this Section 1(b), being sometimes hereinafter individually and/or collectively referred to as the "Trademarks");

- (c) the goodwill of Pledgor's business connected with and symbolized by the Trademarks; and
- (d) copyrights, and copyright applications, including without limitation, those copyrights listed in Schedule C (being sometimes referred to individually and/or collectively as the "Copyrights");

together with all additions, accessions, accessories, amendments, attachments, modifications, substitutions, and replacements, proceeds and products of the foregoing.

2. Recording of Patents and Trademarks. Pledgor represents and warrants that (1) the patents and patent applications listed in Schedule A, and (2) the trademark and trademark applications described in Schedule B, have each been duly recorded in the U.S. Patent and Trademark Office (the "PTO"); and that no other patents, patent applications, trademarks, or trademark applications have been filed or recorded with the PTO in which the Pledgor has an interest.

3. Recording of Copyrights. Pledgor represents and warrants that the copyright and copyright applications described in Schedule C have been duly recorded in the U.S. Copyright Office, and that no other copyright, and copyright applications have been recorded in the U.S. Copyright Office, in which the Pledgor has an interest.

4. Restrictions on Future Agreements. Pledgor will not, without the Lender's prior written consent, after the date hereof, enter into any agreement, including, without limitation, any license agreement, that is inconsistent with this Agreement, and Pledgor further agrees that it will not take any action, and will use reasonable efforts not to knowingly permit any action to be taken by others subject to its control, including licensees, or knowingly fail to take any action, which would affect the validity or enforcement of the rights transferred to the Lender, under this Agreement or the rights associated with those Patents, Trademarks and/or Copyrights which are

in Pledgor's reasonable business judgment, necessary or desirable in the operation of Pledgor's business.

5. New Patents, Trademarks and Copyrights. Pledgor represents and warrants that the Patents, Trademarks, and Copyrights listed on Schedules A, B, and C, include all of the patents, patent applications, trademark registrations, trademark applications, service marks registrations, service mark applications, registered copyrights and copyright applications, now owned or held by Pledgor. If, prior to the termination of this Agreement, Pledgor shall (i) create or obtain rights to any new patents, trademarks, trademark registrations, trademark applications, trade names, trade styles, service marks, service marks registrations, or service mark applications, or (ii) become entitled to the benefit of any patent, trademark, trademark registration, trademark application, trade name, trade style, service mark, service mark registration, service mark application, the provisions of Section 1 above shall automatically apply thereto and Pledgor shall give the Lender prompt written notice thereof. Pledgor hereby authorizes the Lender to modify this Agreement by (a) amending Schedules A, B, and/or C, as the case may be, to include any future patents, trademark registrations, trademark applications, service mark registrations, service mark applications, registered copyrights and copyright applications that are Patents, Trademarks or Copyrights under Section 1 above, or under this Section 5 (whether or not any such notice from Pledgor has been sent or received), and (b) filing, in addition to and not in substitution for this Agreement, a supplement or addendum to this Agreement containing on Schedule B therein, as the case may be, such registered trademarks, trademark applications, service marks, registered service marks and service mark applications that are Trademarks under Section 1 above or this Section 5 and to take any action the Lender otherwise deems appropriate to perfect or maintain the rights and interest of the Lender, under this Agreement with respect to such Patents, Trademarks and Copyrights.

6. Nature and Continuation of Security Interest; Notice to Third Parties. This Agreement has the effect of giving third parties notice of the Lender's Security Interest in Company's Patents, Trademarks and Copyrights. This Agreement is made for collateral security purposes only. This Agreement shall create a continuing security interest in the Patents, Trademarks and Copyrights and shall remain in full force and effect until the liabilities and Obligations of the Company to the Lenders have been paid in full. Notwithstanding anything to the contrary contained herein, it is understood and agreed that the Lender's security interest in the Patents, Trademarks and Copyrights set forth on Schedule D shall be subject to the license granted by the Pledgor to Ethicon Endo-Surgery, Inc. ("Ethicon") pursuant to the Distribution Agreement, dated as of September 28, 1999, between the Company and Ethicon, as amended to date. So long as Ethicon is performing its obligations and not otherwise in default under said Distribution Agreement, such license shall continue in accordance with its terms, notwithstanding any action of Lender taken hereunder upon and after an Event of Default; provided, that, it is understood and agreed that the Lender, upon and after an Event of Default, shall be entitled to all payments made by Ethicon or its assigns in respect of such Patents, Trademarks and Copyrights. Pledgor hereby authorizes the Secured Party to register and record the security interest granted hereby at the PTO and to file any necessary financing statements with the Secretary of State of the State of Delaware to evidence the security interest granted hereby.

7. Right to Inspect; Assignments and Security Interests. The Lender shall have the right, at any reasonable time upon prior written request and from time to time, to inspect Pledgor's premises and to examine Pledgor's books, records and operations relating to the Patents and the Trademarks, including, without limitation, Pledgor's quality control processes; provided, that in conducting such inspections and examinations, the Lender shall use reasonable efforts not to disturb unnecessarily the conduct of Pledgor's ordinary business operations. From and after the occurrence of an event of default under the Notes (an "Event of Default"), Pledgor agrees that the Lender, or a conservator appointed by the Lender, shall have the right to take any action to renew or to apply for registration of any Trademarks as the Lender or said conservator, on its sole judgment, may deem necessary or desirable in connection with the enforcement of the Lender's rights hereunder. Pledgor agrees not to sell or assign its respective interests in the Patents, Trademarks and/or Copyrights without the prior written consent of the Lender.

8. Duties of Pledgor. Pledgor shall have the duty to (i) prosecute diligently any patent application, or trademark application or service mark application that is part of the Trademarks pending as of the date hereof or thereafter until the termination of this Agreement, and (ii) preserve and maintain all of Pledgor's rights in the patents, patent applications, trademark applications, service mark applications and trademark and service mark registrations that are part of the Patents and Trademarks. Any expenses incurred in connection with the foregoing shall be borne by Pledgor. Pledgor shall not, without thirty (30) days prior written notice to the Lender, abandon any trademark or service mark that is the subject of a registered trademark, service mark or application therefor and which, is or shall be necessary or economically desirable in the operation of the Pledgor's business. The Lender shall not have any duty with respect to the Patents, Trademarks and/or Copyrights. Without limiting the generality of the foregoing, the Lender shall not be under any obligation to take any steps necessary to preserve rights in the Patents, Trademarks and/or Copyrights against any other parties, but may do so at its option during the continuance of an Event of Default, and all expenses incurred in connection therewith shall be for the sole account of Company and added to the Obligations and liabilities secured hereby and by the Security Agreement. Pledgor covenants and agrees to take all necessary steps (at Pledgor's sole cost and expense) to perfect the Lender's security interest in the Patents, Trademarks and Copyrights in any foreign jurisdiction (other than the State of Israel) within 90 days of the date hereof, and to provide evidence of the same to the Lender.

9. Lender's Right to Sue. Upon the occurrence and during the continuance of any Event of Default, the Lender shall have the right, for the benefit of the Lenders, to exercise all rights and remedies available at law or in equity. From and after the occurrence and during the continuance of an Event of Default, the Lender shall have the right, but shall not be obligated, to bring suit or take any other action to enforce the Patents, Trademarks and Copyrights and, if the Lender shall commence any such suit or take any such action, Pledgor shall, at the request of the Lender, do any and all reasonable lawful acts and execute any and all proper documents reasonably required by the Lender in aid of such enforcement. Pledgor shall, upon demand, promptly reimburse and indemnify the Lender for all reasonable out-of-pocket costs and expenses incurred by the Lender in the exercise of its rights under this Section 9 (including, without limitation, all attorneys' fees). If, for any reason whatsoever, the Lender is not

reimbursed with respect to the costs and expenses referred to in the preceding sentence, such costs and expenses shall be added to the Obligations secured hereby and by the Security Agreement.

10. Waivers. The Pledgor waives to the extent permitted by applicable law presentment, demand, notice, protest, notice of acceptance of this Agreement, notice of any loans made, credit or other extensions granted, collateral received or delivered or any other action taken in reliance hereon and all other demands and notices of any description, except for such demands and notices as are expressly required to be provided to the Pledgor under this Agreement or any other document evidencing the Obligations or the liabilities under the Notes. With respect to both the Obligations and any collateral securing the Notes (the "Collateral"), the Pledgor assents to any extension or postponement of the time of payment or any other forgiveness or indulgence, to any substitution, exchange or release of Collateral, to the addition or release of any party or person primarily or secondarily liable, to the acceptance of partial payment thereon and the settlement, compromise or adjustment of any thereof, all in such manner and at such time or times as the Lender may deem advisable. The Lender may exercise its rights with respect to the Collateral without resorting, or regard, to other collateral or sources of reimbursement for Obligations. The Lender shall not be deemed to have waived any of its rights with respect to the Obligations or the Collateral unless such waiver is in writing and signed by the Lender. No delay or omission on the part of the Lender in exercising any right shall operate as a waiver of such right or any other right. A waiver on any one occasion shall not bar or waive the exercise of any right on any future occasion. All rights and remedies of the Lender in the Obligations or the Collateral, whether evidenced hereby or by any other instrument or papers, are cumulative and not exclusive of any remedies provided by law or any other agreement, and may be exercised separately or concurrently.

11. Successors and Assigns. This Agreement shall be binding upon the Pledgor, its respective successors and permitted assigns, and shall inure to the benefit of and be enforceable by the Lender and its successors and assigns. Without limiting the generality of the foregoing sentence, the Lender may assign or otherwise transfer any agreement or any note held by it evidencing, securing or otherwise executed in connection with the Obligations, or sell participations in any interest therein, to any other person or entity.

12. General; Term.

(a) This Agreement may not be amended or modified except by a writing signed by the Pledgor and the Lender, nor may the Pledgor assign any of its rights hereunder. This Agreement and the terms, covenants and conditions hereof shall be construed in accordance with, and governed by, the laws of the State of New York (without giving effect to any conflicts of law provisions contained therein). In the event that any Collateral stands in the name of the Pledgor and another or others jointly, as between the Lender and the Pledgor, the Lender may deal with the same for all purposes as if it belonged to or stood in the name of the Pledgor alone.

(b) This Agreement and the security interests granted herein shall terminate on the date on which all payments under the Notes have been indefeasibly paid or satisfied in full

(including as a result of the conversion in full of the Notes) and all other obligations have been paid or discharged (other than contingent indemnification obligations).

13. Waiver of Jury Trial; Venue. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. The Pledgor agrees that all proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement, the other Transaction Documents (as defined in the Purchase Agreement) and the Notes (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) may be brought in the Courts of New York County, New York or of the United States of America for the Southern District of New York and hereby expressly submits to the personal jurisdiction and venue of such courts for the purposes thereof and expressly waives any claim of improper venue and any claim that such courts are an inconvenient forum. Each of the Pledgor and the Lender hereby irrevocably consents to the service of process of any of the aforementioned courts in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, at the address in effect for notices to it under the Purchase Agreement, such service to become effective 10 days after such mailing. Nothing in this Section shall affect or limit any right to serve process in any other manner permitted by law. Each of the Pledgor and the Lender hereby agree that the prevailing party in any suit, action or proceeding arising out of or relating to this Agreement shall be entitled to reimbursement for reasonable legal fees from the non-prevailing party. The Pledgor and the Lender hereby waive all rights to trial by jury.

*[Signature Page Follows]*


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

**PLEDGOR:**

In the Presence of:

  
Witness


NEOPROBE CORPORATION

By:   
Name: David Burr  
Title: President & CEO


In the Presence of:

  
Witness


CARDIOSONIX LTD

By:   
Name: David Burr  
Title: Chairman

In the Presence of:


  
Witness

CIRA BIOSCIENCES INC.


By:   
Name: David Burr  
Title: Chairman

**LENDER:**

In the Presence of:

  
Witness

PLATINUM MONTAUR LIFE SCIENCES, LLC

By:   
Name: Michael Goldberg  
Title: Portfolio Manager



**SCHEDULE A**  
**Patents and Patent Applications**

**Patents held by Neoprobe Corporation**

<b>Holder</b>	<b>Patent / Application No.</b>	<b>Issue / Filing Date</b>	<b>Description</b>
Neoprobe Corporation	US4889991	26-Dec-89	Gamma radiation detector with enhanced signal treatment
Neoprobe Corporation	US5151598	29-Sep-92	Detector and localizer for low energy radiation emissions
Neoprobe Corporation	US5383456	24-Jan-95	Radiation-based laparoscopic method for determining treatment modality
Neoprobe Corporation	US5429133	04-Jul-95	Radiation responsive laparoscopic instrument
Neoprobe Corporation	US5441050	15-Aug-95	Radiation responsive surgical instrument
Neoprobe Corporation	US5475219	12-Dec-95	Validation of photon emission based signals using an energy window network in conjunction with a fundamental mode discriminator circuit
Neoprobe Corporation	US5682888	14-Nov-97	Apparatus and system for detecting and locating photon emissions with remote switch control
Neoprobe Corporation	US5732704	31-Mar-98	Radiation based method for locating and differentiating sentinel nodes
Neoprobe Corporation	US5857463	12-Jan-99	Remotely controlled apparatus and system for tracking and locating a source of photoemissions
Neoprobe Corporation	US5928150	27-Jul-99	System for locating and detecting a source of photon emissions
Neoprobe Corporation	US5987350	16-Nov-99	Surgical probe apparatus and system
Neoprobe Corporation	US6144876	07-Nov-00	Scanning a radiation source with a count rate output derived w/ dynamic window
Neoprobe Corporation	US6191422	20-Feb-01	Radiation probe with compound semiconductor crystal performing in a trapping-dependent operational mode
Neoprobe Corporation	US6204505	20-Mar-01	Surgical probe apparatus and system
Neoprobe Corporation	US6218669	17-Apr-01	Surgical probe apparatus
Neoprobe Corporation	US6222193	24-Apr-01	Radiation responsive surgical probe apparatus
Neoprobe Corporation	US6259095	10-Jul-01	System and apparatus for detecting and locating sources of radiation
Neoprobe Corporation	US6272373	07-Aug-01	Scanning system and method for locating sources of radiation emissions
Neoprobe Corporation	D390480	10-Feb-98	Detector unit for radiation detecting probe
Neoprobe Corporation	D390481	10-Feb-98	Radiation detecting probe
Neoprobe Corporation	D390485	10-Feb-98	Handle unit for radiation detecting probe
Neoprobe Corporation	D400249	27-Oct-98	Console for controlling a radiation probe
Neoprobe Corporation	D411118	22-Jun-99	Console for controlling a radiation probe

TRADEMARK

REEL: 003699 FRAME: 0342

Holder	Patent / Application No.	Issue / Filing Date	Description
Neoprobe Corporation	D411468	29-Jun-99	Console for controlling a radiation probe - Medium scope
Neoprobe Corporation	D412125	20-Jul-99	Console for controlling a radiation probe - Broad scope
Neoprobe Corporation	D413532	07-Sep-99	Radiation detecting probe
Neoprobe Corporation	D413533	07-Sep-99	Console for controlling radiation detecting probe - Narrow scope
Neoprobe Corporation	D423377	25-Apr-00	Radiation detecting probe
Neoprobe Corporation	D424453	09-May-00	Detector unit for radiation detecting probe

#### Patents held by Subsidiaries

Cardiosonix Ltd.	US6503205	07-Jan-03	Dual ultrasonic transducer probe for blood flow measurement
Cardiosonix Ltd.	US6719698B	14-Apr-04	Ultrasonic transducer probe and a measurement device utilizing same

#### Patents (Applications) In-Licensed by Neoprobe Corporation

University of California Board of Regents	6,409,990	25-Jun-02	Macromolecular carrier for drug or diagnostic delivery
University of California Board of Regents	EU 1178838 –	24-Sep-2004	Claims mirror 6,409,990 - ratified in Germany, France, Spain, Great Britain, Italy, Netherlands and Sweden
University of California Board of Regents	Patent application (Japan)		Claims mirror 6,409,990 - notification of allowance has been received
Dow Chemical / NIH	5,512,443	30-Apr-96	TAG-72 antibodies including CC49
Dow Chemical / NIH	5,993,813	30-Nov-99	Chimeric versions of CC49
Dow Chemical / NIH	6,051,225	18-Apr-00	Humanized versions of antibodies including CC49 (Japan - claims granted; EU examination in process)
Dow Chemical / NIH	6,207,815	27-Mar-01	Chimeric TAG-72 antibodies
Dow Chemical / NIH	6,495,137	17-Dec-02	Humanized TAG-72 antibodies
Dow Chemical / NIH	Patent application (2003,0165498)	4-Sep-03	Novel composite and humanized antibodies w/ TAG-72
Cira Biosciences	5,814,295	29-Sep-1998	Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
Cira Biosciences	6,093,381	25-Jul-2000	Modulation of the sensitivity of tumor cells to chemotherapeutics
Cira Biosciences	6,713,054B1	20-Mar-2004	Cellular immunotherapy treatment of patients afflicted with chronic fatigue syndrome
Cira Biosciences	Patent application		Adoptive cellular therapy treatment of patients afflicted with viral diseases including HIV and Hep-C

#### Pending Patent Applications / Patent Applications in Process

None

**SCHEDULE B  
Trademarks and Trademark Applications**

**Trademarks held by Neoprobe Corporation**

<b>Trademark</b>	<b>U.S. Registration #</b>	<b>OUS Registration #</b>	
BlueTip	2432380		
Cardiosonix	2728058	002769370	European Union
Lymphoseek	3163525		
neo2000	2322304		
NeoMax	2450105		
Neoprobe	2316583	151006 541191 33254994 2079214 665552 310007 1787313 1787314 259040 784400 800774 1551932 Appl #97/04602	Austria Benelux France Germany Italy South Korea Spain Spain Sweden Taiwan Taiwan United Kingdom Malaysia 04/97
Neoprobe and Design		446971	South Korea
Quantix	2762894	003738267	European Union
RIGS	1542372	93489489 2079213 665553 325396 1551934	France Germany Italy Sweden United Kingdom
RIGScan		93489490 2079212 665554 266203 1551936	France Germany Italy Sweden United Kingdom

**Domain Names registered**

neoprobe.com  
neoprobe.net  
neoprobe.org  
cardiosonixltd.com  
cardiosonix.net  
cardiosonix.org  
neoprobe.us  
cardiosonix.us  
cirabio.com  
cirabio.net  
cirabio.org  
cirabiosciences.com  
cirabiosciences.net  
cirabiosciences.org

**SCHEDULE C**  
**Copyrights and Copyright Applications**

**None**

**SCHEDULE D**  
**Ethicon Agreement Intellectual Property**

**Patents held by Neoprobe Corporation**

<b>Holder</b>	<b>Patent / Application No.</b>	<b>Issue / Filing Date</b>	<b>Description</b>
Neoprobe Corporation	US4889991	26-Dec-89	Gamma radiation detector with enhanced signal treatment
Neoprobe Corporation	US5151598	29-Sep-92	Detector and localizer for low energy radiation emissions
Neoprobe Corporation	US5383456	24-Jan-95	Radiation-based laparoscopic method for determining treatment modality
Neoprobe Corporation	US5429133	04-Jul-95	Radiation responsive laparoscopic instrument
Neoprobe Corporation	US5441050	15-Aug-95	Radiation responsive surgical instrument
Neoprobe Corporation	US5475219	12-Dec-95	Validation of photon emission based signals using an energy window network in conjunction with a fundamental mode discriminator circuit
Neoprobe Corporation	US5682888	14-Nov-97	Apparatus and system for detecting and locating photon emissions with remote switch control
Neoprobe Corporation	US5732704	31-Mar-98	Radiation based method for locating and differentiating sentinel nodes
Neoprobe Corporation	US5857463	12-Jan-99	Remotely controlled apparatus and system for tracking and locating a source of photoemissions
Neoprobe Corporation	US5928150	27-Jul-99	System for locating and detecting a source of photon emissions
Neoprobe Corporation	US5987350	16-Nov-99	Surgical probe apparatus and system
Neoprobe Corporation	US6144876	07-Nov-00	Scanning a radiation source with a count rate output derived w/ dynamic window
Neoprobe Corporation	US6191422	20-Feb-01	Radiation probe with compound semiconductor crystal performing in a trapping-dependent operational mode
Neoprobe Corporation	US6204505	20-Mar-01	Surgical probe apparatus and system
Neoprobe Corporation	US6218669	17-Apr-01	Surgical probe apparatus
Neoprobe Corporation	US6222193	24-Apr-01	Radiation responsive surgical probe apparatus
Neoprobe Corporation	US6259095	10-Jul-01	System and apparatus for detecting and locating sources of radiation
Neoprobe Corporation	US6272373	07-Aug-01	Scanning system and method for locating sources of radiation emissions
Neoprobe Corporation	D390480	10-Feb-98	Detector unit for radiation detecting probe
Neoprobe Corporation	D390481	10-Feb-98	Radiation detecting probe
Neoprobe Corporation	D390485	10-Feb-98	Handle unit for radiation detecting probe
Neoprobe Corporation	D400249	27-Oct-98	Console for controlling a radiation probe
Neoprobe Corporation	D411118	22-Jun-99	Console for controlling a radiation probe

Holder	Patent / Application No.	Issue / Filing Date	Description
Neoprobe Corporation	D411468	29-Jun-99	Console for controlling a radiation probe - Medium scope
Neoprobe Corporation	D412125	20-Jul-99	Console for controlling a radiation probe - Broad scope
Neoprobe Corporation	D413532	07-Sep-99	Radiation detecting probe
Neoprobe Corporation	D413533	07-Sep-99	Console for controlling radiation detecting probe - Narrow scope
Neoprobe Corporation	D423377	25-Apr-00	Radiation detecting probe
Neoprobe Corporation	D424453	09-May-00	Detector unit for radiation detecting probe

**Trademarks held by Neoprobe Corporation**

Trademark	U.S. Registration #	OUS Registration #	
BlueTip	2432380		
neo2000	2322304		
NeoMax	2450105		
Neoprobe	2316583	151006 541191 33254994 2079214 665552 310007 1787313 1787314 259040 784400 800774 1551932 Appl #97/04602	Austria Benelux France Germany Italy South Korea Spain Spain Sweden Taiwan Taiwan United Kingdom Malaysia 04/97
Neoprobe and Design		446971	South Korea

**Domain Names registered**

neoprobe.com  
neoprobe.net  
neoprobe.org  
neoprobe.us